📣 VC round data is live. Check it out!
- Public Comps
- Masimo
Masimo Valuation Multiples
Discover Masimo's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Baxter International, Insulet, Bruker, Demant and more.
Masimo Overview
About Masimo
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
Founded
1989
HQ

Employees
9.2K
Website
Financials (LTM)
EV
$10B
Valuation Multiples
Start free trialMasimo Financials
Masimo reported last 12-month revenue of $2B and EBITDA of $475M.
In the same LTM period, Masimo generated $475M in EBITDA and $17M in net income.
Revenue (LTM)
Masimo P&L
In the most recent fiscal year, Masimo reported revenue of $2B and EBITDA of $495M.
Masimo is profitable as of last fiscal year, with gross margin of 58%, EBITDA margin of 30%, and net margin of 15%.
Financial data powered by Morningstar, Inc.
Masimo Stock Performance
Masimo has current market cap of $9B, and enterprise value of $10B.
Market Cap Evolution
Masimo's stock price is $178.71.
Masimo share price increased by 0.1% in the last 30 days, and by 6.2% in the last year.
Masimo has an EPS (earnings per share) of $4.74.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10B | $9B | 0.1% | 0.1% | 0.5% | 6.2% | $4.74 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMasimo Valuation Multiples
Masimo trades at 6.2x EV/Revenue multiple, and 20.4x EV/EBITDA.
EV / Revenue (LTM)
Masimo Financial Valuation Multiples
As of June 3, 2026, Masimo has market cap of $9B and EV of $10B.
Masimo has a P/E ratio of 548.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Masimo Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Masimo Margins & Growth Rates
Masimo grew revenue by 8% and EBITDA by 12% in the last fiscal year.
In the most recent fiscal year, Masimo reported gross margin of 58%, EBITDA margin of 30%, and net margin of 15%.
Masimo Margins
Masimo Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Masimo Operational KPIs
Masimo's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Masimo's Rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Masimo's Rule of X is 23% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Masimo Competitors
Masimo competitors include Baxter International, Insulet, Bruker, Demant, Bio-Rad Laboratories, Globus Medical, Zydus Lifesciences, Fresenius Medical Care, Cooper Companies and Shimadzu.
Most Masimo public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.5x | 1.5x | 7.6x | 7.8x | |||
| 3.8x | 3.5x | 16.1x | 14.5x | |||
| 3.0x | 2.9x | 19.2x | 17.6x | |||
| 3.1x | 3.0x | 13.1x | 12.6x | |||
| 3.1x | 3.1x | 6.6x | 18.1x | |||
| 3.4x | 3.3x | 11.0x | 10.3x | |||
| 4.2x | 4.1x | 13.4x | 15.8x | |||
| 1.0x | 1.0x | 5.2x | 5.3x | |||
This data is available for Pro users. Sign up to see all Masimo competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Masimo
Masimo has acquired 4 companies to date.
Last acquisition by Masimo was on April 20th 2023. Masimo acquired nura for undisclosed valuation.
Latest Acquisitions by Masimo
| Description | nura is an Australian audio company known for the Nuraphone headphones, which feature biometric sensors to measure hearing profiles from outer ear to brain and customize sound output. Founded in 2014 in Melbourne, the technology adapts EQ settings automatically upon wear detection. The Nuraphone supports wireless Bluetooth connectivity and immersive 360-degree audio. nura has expanded to true wireless earbuds and sells through retailers in Europe, Asia, and North America, with patents on its sensory technology. | Sound United is a consumer audio company owning brands Polk Audio, Definitive Technology, and Denon home theater systems. Montebello, California-headquartered after a 2017 merger with D+M Holdings, it manufactures wireless speakers, soundbars, and AV receivers distributed globally via Best Buy and Amazon. The portfolio includes Marantz hi-fi amplifiers and HEOS multi-room streaming compatible with AirPlay 2. | LiDCO is a Cambridge-headquartered medical device company manufacturing non-invasive and minimally invasive hemodynamic monitoring systems. Its LiDCOplus and LiDCOrapid monitors measure pulse contour analysis for cardiac output, oxygen delivery, and fluid responsiveness in ICU and surgical settings. Deployed in over 2,000 hospitals globally, the technology supports goal-directed therapy reducing complications in high-risk patients. Since introducing its first product in 1999, LiDCO integrates with existing clinical monitors for real-time hemodynamic optimization. | TNI medical is a medical device company headquartered in Freiburg, Germany, specializing in non-invasive respiratory therapy equipment. The firm develops the SoftFlow system, a high-flow nasal cannula device that delivers heated, humidified oxygen to improve patient comfort during ventilation. Production facilities operate in Würzburg and Dessau in Germany, alongside a U.S. site in Baltimore, Maryland. Founded in 2007, TNI medical distributes its products to hospitals and clinics worldwide, emphasizing therapy for chronic obstructive pulmonary disease and acute respiratory distress. |
| HQ Country | ||||
| HQ City | Melbourne | San Diego, CA | London | Freiburg |
| Deal Date | 20 Apr 2023 | 15 Feb 2022 | 2 Nov 2020 | 20 Mar 2020 |
| Valuation | undisclosed | $1B | $40M | $33M |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Masimo acquisitions and their M&A valuation multiples. Start Free Trial | ||||
Investments by Masimo
Masimo has invested in 1 company to date.
Latest investment by Masimo was on January 3rd 2018. Masimo invested in StartUp Health in their $19M Undisclosed stage round (EV/Revenue multiple available to Pro users).
Latest Investments by Masimo
| Description | StartUp Health is a New York-headquartered venture platform founded in 2011 that invests in over 400 health technology companies spanning six continents and 26 countries. Its portfolio targets moonshots in access to care, disease cures, women's health, mental health, longevity, and pandemic response, with companies collectively raising more than $2 billion. Backed by investors such as Kaiser Permanente, Novartis, Steve Case, and Mark Cuban, the platform delivers decade-long support including capital, expert networks, and strategic collaborations. |
| HQ Country | |
| HQ City | New York City, NY |
| Deal Date | 3 Jan 2018 |
| Round | Undisclosed stage |
| Raised | $19M |
| Investors | GuideWell; Masimo; Ping An |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Masimo investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Masimo
| When was Masimo founded? | Masimo was founded in 1989. |
| Where is Masimo headquartered? | Masimo is headquartered in United States. |
| How many employees does Masimo have? | As of today, Masimo has over 9K employees. |
| Who is the CEO of Masimo? | Masimo's CEO is Catherine M. Szyman. |
| Is Masimo publicly listed? | Yes, Masimo is a public company listed on Nasdaq. |
| What is the stock symbol of Masimo? | Masimo trades under MASI ticker. |
| When did Masimo go public? | Masimo went public in 2007. |
| Who are competitors of Masimo? | Masimo main competitors include Baxter International, Insulet, Bruker, Demant, Bio-Rad Laboratories, Globus Medical, Zydus Lifesciences, Fresenius Medical Care, Cooper Companies, Shimadzu. |
| What is the current market cap of Masimo? | Masimo's current market cap is $9B. |
| What is the current revenue of Masimo? | Masimo's last 12 months revenue is $2B. |
| What is the current revenue growth of Masimo? | Masimo revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Masimo? | Current revenue multiple of Masimo is 6.2x. |
| What is the current EBITDA of Masimo? | Masimo's last 12 months EBITDA is $475M. |
| What is Masimo's EBITDA margin? | Masimo's last 12 months EBITDA margin is 30%. |
| What is the current EV/EBITDA multiple of Masimo? | Current EBITDA multiple of Masimo is 20.4x. |
| What is the current FCF of Masimo? | Masimo's last 12 months FCF is $196M. |
| What is Masimo's FCF margin? | Masimo's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Masimo? | Current FCF multiple of Masimo is 49.6x. |
| How many companies Masimo has acquired to date? | As of June 2026, Masimo has acquired 4 companies. |
| What was the largest acquisition by Masimo? | $1B acquisition of Sound United on 15th February 2022 was the largest M&A Masimo has done to date. |
| What companies Masimo acquired? | Masimo acquired Sound United, Lidco, TNI medical, and nura. |
| In how many companies Masimo has invested to date? | As of June 2026, Masimo has invested in 1 company. |
| What was the last Masimo investment? | On 3rd January 2018 Masimo invested in StartUp Health, participating in a $19M Undisclosed stage round, alongside GuideWell and Ping An. |
| In what companies Masimo invested in? | Masimo invested in StartUp Health. |
See public comps similar to Masimo
Lists including Masimo
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.



